BioCatalyst

Brenetafusp, Brenetafusp and pembrolizumab, Brenetafusp and chemotherapy, Brenetafusp and monoclonal antibodies and chemotherapy — catalyst calendar

1 verified catalyst event(s) referencing Brenetafusp, Brenetafusp and pembrolizumab, Brenetafusp and chemotherapy, Brenetafusp and monoclonal antibodies and chemotherapy, each linked to its official source. Verified as of 2026-06-22.

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-10 (month)
in 3mo
ESTIMATED
 READOUT
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Check
Phase 1/2 · Select Advanced Solid Tumors
 IMCR Immunocore Holdings plc Brenetafusp, Brenetafusp and pembrolizum ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.